E
Evan Y. Yu
Researcher at University of Washington
Publications - 330
Citations - 19023
Evan Y. Yu is an academic researcher from University of Washington. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 44, co-authored 264 publications receiving 14899 citations. Previous affiliations of Evan Y. Yu include Seattle Cancer Care Alliance & Harvard University.
Papers
More filters
Journal ArticleDOI
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
Anna J. Black,Homayoun Zargar,Kamran Zargar-Shoshtari,Kamran Zargar-Shoshtari,Adrian Fairey,Laura S. Mertens,Colin P.N. Dinney,Maria Carmen Mir,Laura Maria Krabbe,Laura Maria Krabbe,Michael S. Cookson,Niels Jacobsen,Joshua Griffin,Jeffrey S. Montgomery,Nikhil Vasdev,Nikhil Vasdev,Evan Y. Yu,Evanguelos Xylinas,Evanguelos Xylinas,Nicholas J. Campain,Wassim Kassouf,Marc A. Dall'Era,Jo An Seah,Cesar E. Ercole,Simon Horenblas,John S. McGrath,Jonathan Aning,Shahrokh F. Shariat,Shahrokh F. Shariat,Jonathan L. Wright,Andrew C. Thorpe,Todd M. Morgan,Jeff M. Holzbeierlein,Trinity J. Bivalacqua,Scott North,Scott North,Daniel A. Barocas,Yair Lotan,Petros Grivas,Petros Grivas,Andrew J. Stephenson,Jay B. Shah,Jay B. Shah,Bas W.G. van Rhijn,Philippe E. Spiess,Siamak Daneshmand,Srikala S. Sridhar,Peter C. Black +47 more
TL;DR: NLR > 3 was associated with a decreased response to NAC and shorter disease-specific and overall survival, which suggests that NLR is a simple tool that can aid in MIBC risk stratification in clinical practice.
Journal ArticleDOI
The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic carcinoma.
TL;DR: The data suggest that mutations of the p53 tumour suppressor gene may be associated with increased angiogenesis in CaP and this relationship potentially has therapeutic implications.
Journal ArticleDOI
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
Gabriella Del Bene,Fabio Calabrò,Diana Giannarelli,Elizabeth R. Plimack,Lauren C. Harshman,Evan Y. Yu,Simon J. Crabb,Sumanta K. Pal,Ajjai Alva,Thomas Powles,Ugo De Giorgi,Neeraj Agarwal,Aristotelis Bamias,Sylvain Ladoire,Andrea Necchi,Ulka N. Vaishampayan,Günter Niegisch,Joaquim Bellmunt,Jack Baniel,Matthew D. Galsky,Cora N. Sternberg +20 more
TL;DR: This study demonstrates superiority in DFS for NC compared to AC and the positive prognostic impact of complete pathological response to NC was confirmed, demonstrating superiority in overall survival and disease-free survival.
Journal ArticleDOI
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
Daniel P. Petrylak,Elisabeth I. Heath,G. Sonpavde,Saby George,Alicia K. Morgans,B.J. Eigl,Joel Picus,S. Cheng,Sebastien J. Hotte,Elaina M. Gartner,M. Vincent,R. Chu,Banmeet Anand,Katherine M. Morrison,L. Jackson,Amal Melhem-Bertrandt,Evan Y. Yu +16 more
Journal ArticleDOI
A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Kim N. Chi,Sebastien J. Hotte,Susan Ellard,Joel Roger Gingerich,Anthony M. Joshua,Christian Kollmannsberger,Evan Y. Yu,Martin E. Gleave +7 more
TL;DR: Preliminary data provide clinical support for the role of Hsp27 in AR signalling and as a therapeutic target for prostate cancer in patients with CRPC and any prior treatment other than chemotherapy.